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Cancer stem cells (CSCs) display plasticity and self-renewal properties reminiscent of normal tissue stem cells,
but the events responsible for their emergence remain obscure. We recently identified CSCs in Ewing sarcoma
family tumors (ESFTs) and showed that they retain mesenchymal stem cell (MSC) plasticity. In the present study,
we addressed the mechanisms that underlie ESFT CSC development. We show that the EWS-FLI-1 fusion gene,
associated with 85%–90% of ESFTs and believed to initiate their pathogenesis, induces expression of the
embryonic stem cell (ESC) genes OCT4, SOX2, and NANOG in human pediatric MSCs (hpMSCs) but not in their
adult counterparts. Moreover, under appropriate culture conditions, hpMSCs expressing EWS-FLI-1 generate a cell
subpopulation displaying ESFT CSC features in vitro. We further demonstrate that induction of the ESFT CSC
phenotype is the result of the combined effect of EWS-FLI-1 on its target gene expression and repression of
microRNA-145 (miRNA145) promoter activity. Finally, we provide evidence that EWS-FLI-1 and miRNA-145
function in a mutually repressive feedback loop and identify their common target gene, SOX2, in addition to
miRNA145 itself, as key players in ESFT cell differentiation and tumorigenicity. Our observations provide insight
for the first time into the mechanisms whereby a single oncogene can reprogram primary cells to display a CSC
phenotype.
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Hematopoietic malignancies as well as a growing number
of solid tumors have been shown to contain a subpopula-
tion of cells possessing tumor-initiating capability asso-
ciated with stem cell properties that include expression of
embryonic stem cell (ESC) genes and asymmetric di-
vision (Clarke et al. 2006). These cells, termed cancer
stem cells (CSCs), are generally believed to represent the
tumor repopulating force, preserving their own numbers
through self-renewal, and generating more differentiated
progeny that compose the bulk of the tumor (Clarke et al.
2006). Such cells should, in principle, be able to arise by at
least two mechanisms: transformation of resident stem
cells within a tissue that allows them to maintain their
‘‘stemness’’ in the transformed state, or genetic repro-
gramming of differentiated somatic cells during trans-
formation that endows them with stem cell properties.
Recent work has identified a small number of transcrip-
tion factors normally expressed in ESCs—including
OCT4, SOX2, NANOG, C-MYC, KLF4, and LIN28—that
can reprogram fibroblasts and other differentiated cells to
acquire pluripotency and become what have been termed
human induced pluripotent stem cells (hiPSs) (Jaenisch
and Young 2008). Thus, it is conceivable that transfor-
mation of primary differentiated or lineage-committed
cells may incur similar reprogramming, and that some
degree of reprogramming may even be inherent to trans-
formation itself. In support of these views, loss of the
retinoblastoma (RB) gene that occurs in a wide variety of
malignancies has been shown to cause primary mouse
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embryonic fibroblasts (MEFs) to undergo reprogramming
and acquire CSC properties (Liu et al. 2009). In addition,
recent observations suggest that two major tumor sup-
pressor genes, INK4A and TP53, impair efficient iPS gener-
ation (Banito et al. 2009; Kawamura et al. 2009; Marion
et al. 2009), consistent with the existence of a relationship
between genetic reprogramming and transformation.
Some types of cancer, including a subset of sarcomas and
hematopoietic malignancies, can, at least in their early
phases, display only a single detectable oncogenic event,
usually in the form of a nonrandom reciprocal chromo-
somal translocation. Chromosomal translocations that
constitute a phenotypic signature of defined tumor types
commonly generate a functional fusion gene believed to
initiate tumor development (Helman and Meltzer 2003).
For transformation and subsequent tumor initiation to
occur, the corresponding fusion protein should be able to
generate CSCs by either exploiting a primary cellular
microenvironment that is permissive for expression of its
oncogenic properties, or early reprogramming of primary
target cells to render them permissive for its subsequent
transforming activity.
Ewing sarcoma family tumors (ESFTs) provide a malig-
nancy of choice to address this issue because they are
associated with a single chromosomal translocation that
appears to be the only detectable oncogenic event in as
many as 20% of the tumors (Riggi and Stamenkovic 2007).
Furthermore, they display both mesenchymal stem cell
(MSC) and neural crest stem cell (NCSC) features, contain
a tumor cell subpopulation with CSC properties, and are
thought to arise from primary MSCs (Suva et al. 2009).
ESFTs constitute a highly aggressive bone and soft tissue
malignancy of children and young adults associated with
a unique chromosomal translocation that generates a fu-
sion protein composed of EWS (or, rarely, FUS/TLS) and
a member of the ets transcription factor family (Riggi et al.
2007). In 85%–90% of cases, the t(11;22)(q24;q12) trans-
location fuses the 59 end of the EWS gene to the 39 end of
the FLI-1 gene, giving rise to the EWS-FLI-1 fusion protein
where sequences containing the potent EWS transactiva-
tion domain are joined to sequences containing the DNA-
binding domain (DBD) of FLI-1 (Delattre et al. 1992).
EWS-FLI-1 behaves as an aberrant transcription factor—
with both inducer and suppressor activity—that displays
distinct target gene specificity from those of its compo-
nent parts (Riggi and Stamenkovic 2007). Expression of
the full transcriptional potential of EWS-FLI-1 is highly
cell context-dependent, as illustrated by its ability to
transdifferentiate neuroblastoma and rhabdomyosarcoma
cells, but to induce p53-dependent growth arrest and apo-
ptosis in primary human embryonic fibroblasts (Lessnick
et al. 2002) and MEFs (Deneen and Denny 2001). We
showed previously that, among primary human cells,
only MSCs display permissiveness for stable EWS-FLI-1
expression without undergoing growth arrest (Riggi et al.
2005, 2008), and that, in mouse mesenchymal progenitor
cells (MPCs), expression of EWS-FLI-1 alone is sufficient to
induce transformation and development of Ewing sarcoma-
like tumors in vivo (Riggi et al. 2005). In adult human
MSCs (hMSCs), EWS-FLI-1 was observed to induce a tran-
scriptome reminiscent of that of Ewing sarcoma, includ-
ing expression of insulin-like growth factor-1 (IGF1), on
whose activity ESFT cells are dependent, and the poly-
comb group gene enhancer of zeste-2 (EZH2) (Riggi et al.
2008). Subsequent work showed that IGF1 is a direct
target of EWS-FLI-1 in MSCs (Cironi et al. 2008), whereas
EZH2, which was found to be highly expressed in primary
ESFTs, plays a central role in the maintenance of Ewing
sarcoma cell line tumorigenicity (Riggi et al. 2008). More
recently, we identified ESFT CSCs (Suva et al. 2009) and
showed that they express the CD133/Prominin-1 stem
cell surface marker in addition to representing the tumor-
initiating population of ESFTs. Interestingly, ESFT CSCs
retain MSC plasticity in vitro, and express genes impli-
cated in ESC maintenance and reprogramming, including
SOX2, OCT4, and NANOG.
To address the mechanisms that may underlie the
emergence of ESFT CSCs, we assessed the effects of
EWS-FLI-1 expression in human pediatricMSCs (hpMSCs),
given that ESFTs are primarily a pediatric/young adult
malignancy. We show that hpMSCs constitute a far more
permissive cellular environment toward EWS-FLI-1 activ-
ity than their adult counterparts, and display gene expres-
sion profile changes that more accurately recapitulate the
molecular profile of ESFT. Moreover, pediatric MSCs
grown in a defined serum-free (henceforth KO) culture
medium undergo genetic reprogramming in response to
EWS-FLI-1, reflected by strong induction of the ESC genes
OCT4, NANOG, and SOX2; the appearance of a NCSC
molecular phenotype; and the generation of a subpopula-
tion of cells that displays ESFT CSC features. We further
provide mechanistic evidence that the robust induction of
SOX2,OCT4, andNANOG associatedwith the emergence
of an ESFT CSC population results in part from the in vivo
repression of themicroRNA-145 (miRNA145) promoter by
EWS-FLI-1. Finally, we uncover the existence of a negative
regulatory feedback loop between EWS-FLI-1 and the
miRNA145, and identify their common target, Sox-2, as
a key player in determining ESFT cell differentiation and
tumorigenicity.
Results
Characterization of pediatric MSCs
hpMSCs were isolated from surgically removed bone of
healthy 6- to 14-yr-old patients undergoing corrective
surgery. Isolation of hpMSCs was performed according to
established protocols (Suva et al. 2004, 2008), and their
cell surface phenotype—as defined by expression of HLA-
ABC, CD90, and CD105, and absence of CD34, CD45,
CD40, CD11b, and CD117—was verified (Fig. 1A). Cells
were maintained in culture at subconfluent concentra-
tions and were periodically assessed for their ability to
differentiate into adipocytes, osteocytes, and chondro-
cytes (Fig. 1B). Cell surface marker expression and differ-
entiation potential were comparable among pediatric and
adult MSC populations. However, proliferation of pedi-
atric MSCs was significantly higher than that of their
adult counterparts (Fig. 1C). Expression of EWS-FLI-1 was
miRNA145 and SOX2 in Ewing sarcoma
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stably maintained in these cells, just as it was in adult
MSCs, and remained unaltered whether the cells were
cultured in standard MSC medium (serum-supplemented)
or in a defined KO medium (Fig. 1D, top panel). Similar to
adult cells, hpMSCs cultured in both serum-supplemented
and KO medium displayed marked rounding following
expression of EWS-FLI-1. However, no difference in pro-
liferation was observed between cells infected with re-
troviruses engineered to express wild-type EWS-FLI-1,
EWS-FLI-1 containing a mutation within the DBD that
precludes its binding toDNA (DBDM) (Welford et al. 2001),
or empty vector (Fig. 1D, bottom panel; data not shown).
The response of pediatric MSCs to EWS-FLI-1 differs
from that of adult MSCs
Gene expression analysis of hpMSCEWS-FLI-1s was per-
formed on RNA from four independent hpMSC isolates
grown in standard serum-supplemented medium 12 d fol-
lowing infection with retrovirus containing EWS-FLI-1.
Comparison of the gene expression profile of these cells
to a primary sarcoma gene expression database (Baird
et al. 2005) revealed highly significant similarity with
the transcriptome of Ewing sarcoma (Fig. 2A), comparable
with that observed between the gene expression profiles
of adult hMSCEWS-FLI-1s and primary ESFTs (Riggi et al.
2008). Qualitative comparison, however, revealed that,
whereas the total number of up-regulated genes shared by
hMSCEWS-FLI-1s and primary Ewing sarcoma did not
change when adult MSCs were substituted by hpMSCs,
the gene repertoire was not identical. Thus, several genes
that were induced in hpMSCs were not induced in adult
MSCs (Fig. 2B), and the same held true when comparison
was made using other databases (Fig. 2C; Staege et al.
2004). Remarkably, the membrane-associated phospholi-
pase A1 b LIPI that has been reported recently to be
a specific ESFT marker (Foell et al. 2008) was induced in
hpMSCs but not in adult MSCs (Fig. 2C). Quantitative
real-time PCR analysis revealed that, whereas LIPI was
up-regulated a little more than twofold in adult MSCs, it
was induced >600-fold in hpMSCs (Fig. 2D, top panel).
Accordingly, whereas LIPI protein expression was un-
detectable in empty vector-infected cells, almost all
hpMSCEWS-FLI-1s displayed strong and homogeneous LIPI
expression (Fig. 2D, bottom panel).
A similar observation was made for the CCK gene that
has been shown to play a role in the tumorigenic potential
of ESFT cell lines (Supplemental Data 1A; Carrillo et al.
2007). Quantitative comparison, by real-time PCR, of the
induction of a panel of EWS-FLI-1 target genes that are
believed to participate in ESFT pathogenesis—including
NKX2-2, IGF1, SOX2,NPY1R,GRP, and EZH2—revealed
that all were more strongly induced in hpMSCs than in
their adult counterparts (Fig. 2E). The stronger transcript
induction could not be attributed to a difference in the
EWS-FLI-1 protein expression level, which was compara-
ble in adult and pediatric MSCs (data not shown). More-
over, among new candidate EWS-FLI-1 target genes
induced in hpMSCEWS-FLI-1s, we identified NTRK1 and
ALK that have been shown to play a critical role in the
development of neuroblastoma (Janoueix-Lerosey et al.
2008; Mosse et al. 2008) and the MEIS1–PBX1 complex
implicated in leukemogenesis (Supplemental Data 1B;
Argiropoulos et al. 2007).
Figure 1. Phenotype of hpMSCs and their permis-
siveness for EWS-FLI-1 expression. (A) FACS charac-
terization of hpMSCs. Cells were labeled with
phycoerythrin (PE)-conjugated antibodies against
CD45, CD40, HLA-ABC, CD105, CD11b, CD34,
CD90, HLA-DR, and CD117, or immunoglobulin
isotype-matched control antibodies. (Colored area)
Control antibody; (white area) specific antibody. (B)
hpMSCs retain the ability to differentiate into adipo-
genic, osteogenic, and chondrogenic lineages upon
stimulation with the appropriate cytokines (for de-
tails, see the Materials and Methods). (Bottom pan-
els) Adipocytic differentiation, oil Red-O staining
(control: medium only); osteoblastic differentiation,
von Kossa staining (control: basal medium); chon-
drocytic differentiation, anti-collagen type II labeling
counterstained with hematoxylin (control: unrelated,
isotype-matched antibody). Magnification: adipocytes
and osteocytes, 2003; chondrocytes, 1003. (C) Com-
parison of the proliferation rate between adult and
pediatric hMSC during a 40-d culture period. (D, top
panel) Western blot analysis of EWS-FLI-1 (E-F)
and DBDM expression in hpMSCs cultured in FCS-
containing or KO medium 12 d after the infection ([E]
empty vector-infected cells). (Bottom panel) MTT
assay analysis of the proliferation rate of hpMSCs
expressing DBDM or EWS-FLI-1 compared with their
empty vector-infected counterparts, cultured in KO or
serum-supplemented conditions.
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MSCs cultured in KO medium culture conditions
display increased permissiveness
for EWS-FLI-1 activity
Recently, the possibility to genetically reprogram differ-
entiated primary mouse and human cells toward iPSs by
expression of a defined core set of transcription factors
(OCT4–SOX2–MYC–KLF4 or OCT4–SOX2–NANOG–
LIN28) followed by specific KO medium culture condi-
tions of the infected cells has been reported (for review,
see Jaenisch and Young 2008). Based on the ability of
EWS-FLI-1 to induce at least two of the reprogramming
factors in hMSC—namely, c-Myc (Dauphinot et al. 2001)
and Sox2 (Riggi et al. 2008)—and the capacity of wild-type
EWS to interact with Oct-4 in vivo and stimulate its
transcriptional activity in ESC (Lee et al. 2005), we
addressed the possibility that EWS-FLI-1 alone might be
able to partially reprogram hpMSCs. Expression of EWS-
FLI-1 in hpMSCs grown under KO culture medium condi-
tions and subjected to the reported reprogramming
protocol (Maherali and Hochedlinger 2008) induced a gene
expression profile bearing the highest similarity to that of
ESFTs observed in a primary cellular context thus far. Com-
parison of the transcriptome of hpMSCEWS-FLI-1s to that of
Figure 2. EWS-FLI-1 expression in hpMSC
induces a gene expression profile that is
distinct from that induced in adult MSC.
(A) Statistical analysis of genes common to
hpMSCEWS-FLI-1 cultured in the presence of
serum and a publicly available soft tissue
tumor gene expression profile database
(Baird et al. 2005). HpMSCEWS-FLI-1s display
remarkable gene expression profile similar-
ity to ESFTs but not to other sarcomas. (B)
List of the 42 genes found to be shared by the
hpMSCEWS-FLI-1 and ESFT gene expression
profiles, and their comparison with the genes
induced in adult hMSCEWS-FLI-1s, demonstrat-
ing the qualitative differences in the mo-
lecular response to EWS-FLI-1 expression
between the two cell types. (C) List of the
15 common genes between hpMSCEWS-FLI-1s
and the ESFT expression signature identified
in another study (Staege et al. 2004), com-
pared with that obtained using adult MSCs.
(D, top panel) Real-time PCR analysis of LIPI
expression levels in empty vector-infected
and EWS-FLI-1-expressing pediatric and
adult hMSCs, showing that the induction
of LIPI is restricted to pediatric cells. (Bot-
tom panel) hpMSCEWS-FLI-1s display strong
homogeneous LIPI protein expression com-
pared with their empty vector-infected
counterparts and similar to the A673 cell
line, as assessed by immunocytochemistry.
Magnification, 1003; inset, 2003. (E) Real-
time PCR assessment of selected EWS-FLI-1
target genes believed to play an important
role in ESFT pathogenesis. Expression of all
of these genes was more strongly induced by
EWS-FLI-1 in hpMSCs than in adult MSCs.
Real-time PCR experiments were normal-
ized to cyclophyllin A and done in triplicate.
Error bars represent the SD of three inde-
pendent determinations. (EWS) Ewing’s sar-
coma; (DFSP) dermatofibrosarcoma; (Lipo)
liposarcoma; (RMS) rhabdomyosarcoma;
(MFH) malignant fibrous histiocytoma;
(OS) osteosarcoma; (HPC) hemangioperi-
cytoma; (GIST) gastrointestinal stromal
tumor; (LMS) leiomyosarcoma; (SS) syno-
vial sarcoma; (MULL) mixed mullerian;
(MPNST) malignant peripheral nerve sheath
tumor; (Fibro) fibrosarcoma.
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the Baird et al. (2005) sarcoma database revealed the number
of induced genes shared by ESFTs and hpMSCEWS-FLI-1s
to almost double when hpMSCEWS-FLI-1s were cultured
in KO rather than in serum-containing medium (79 vs.
42 genes) (Fig. 3A). The overlap with another database
that identified a Ewing sarcoma gene expression signature
Figure 3. hpMSCs cultured in KO stem cell culture conditions display increased permissiveness for EWS-FLI-1 activity and undergo
genetic reprogramming to acquire a NCSC molecular phenotype. (A) Statistical analysis of the genes common to hpMSCEWS-FLI-1s and
the soft tissue tumor gene expression profile database (Baird et al. 2005) presented in Figure 2, showing the marked increase in
similarity between hpMSCEWS-FLI-1s and ESFTs when hpMSCs were cultured in KO conditions. (B) List of the 79 genes found to be shared
by hpMSCEWS-FLI-1s grown in KO culture conditions and the ESFT gene expression profile, and their comparison with the genes induced in
pediatric and adult hMSCEWS-FLI-1s cultured in presence of serum. (C) List of the 19 genes common to hpMSCEWS-FLI-1s cultured in KO
conditions and the ESFT expression signature identified by Staege et al. (2004) compared with results obtained using pediatric and adult
MSCs cultured in the presence of serum. (D) Expression levels of a selected panel of transcripts, currently used to define the NCSC
phenotype, as assessed by real-time PCR, showing induction of all of the genes in hpMSCEWS-FLI-1s cultured in KO medium but not in
serum-supplemented medium. In KO medium-cultured cells only, induction of hNCSC transcripts was accompanied by a concomitant
repression of the two major MSC markers, CD73 and CD44. Real-time PCR experiments were normalized to cyclophyllin A and done in
triplicate. Error bars represent the SD of three independent determinations. For abbreviations, see the legend for Figure 2.
Riggi et al.
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(Staege et al. 2004) was also increased significantly (Fig.
3C). The observed quantitative and qualitative difference
between KO medium-cultured hpMSCEWS-FLI-1 and adult
MSCEWS-FLI-1 expression profiles was even more striking
(Fig. 3B,C).
HpMSCEWS-FLI-1s undergo genetic reprogramming
toward a NCSC and primary ESFT phenotype
Primary ESFTs display both mesenchymal and neuro-
ectodermal features that have fueled a long-standing
debate as to their origin. In light of the recent demon-
stration that, under appropriate culture conditions, hu-
man primary NCSCs (hNCSCs) can give rise to MSCs
(Takashima et al. 2007), induction by EWS-FLI-1 of the
NCSC marker NGFR/p75 in hpMSCs prompted us to
assess the expression of a panel of transcripts currently
used to define the NCSC phenotype. The transcripts
included AP2A, AP2B, NESTIN, PAX3, RET, FOXD3,
POU4F1, TWIST, p75, ALK, and NTRK1. All of these
genes were strongly induced in hpMSCEWS-FLI-1s cultured
in KO medium, as assessed by real-time PCR, but were
either more weakly induced or not induced at all when
the same cells were cultured in the presence of serum.
Their induction was dependent on direct binding of EWS-
FLI-1 to DNA, as hpMSCs expressing the DBDM of the
fusion gene displayed no similarity with either ESFT or
hNCSC databases (data not shown). Some of the tran-
scripts were induced 15-fold to 165-fold, whereas others,
including NGFR/p75, ALK, NTRK1, and AP2B, were
induced several-thousand-fold (Fig. 3D), which is virtu-
ally equivalent to de novo expression. Interestingly, in
KO medium-cultured cells only, induction of hNCSC
transcripts was accompanied by a concomitant repres-
sion of two prominent MSC markers, CD73 and CD44,
consistent with the primary ESFT phenotype, where only
a minority of tumor cells (5%–10%) express cell surface
CD44 and/or CD73 (data not shown). Together, these
observations suggest that the effect of EWS-FLI-1 expres-
sion in hpMSCs cultured in KO medium was not limited
to a mere modulation of transcripts already present in
these cells, but consisted in large part of promoting the
generation of a new cellular phenotype characterized by
the de novo appearance of hNCSC markers.
EWS-FLI-1 expression in hpMSCs induces generation
of a cell subpopulation displaying
an ESFT CSC phenotype
The core gene set required for reprogramming of differ-
entiated cells into iPSs is composed of OCT4, SOX2,
NANOG, C-MYC, KLF4, and LIN28. Because SOX2 and
c-MYC are reported EWS-FLI-1 target genes (Dauphinot
et al. 2001; Riggi et al. 2008), we assessed the expression
level of the remaining genes required for reprogramming
in three different adult and pediatric MSC populations
upon infection with the wild-type or DBDM form of EWS-
FLI-1 in the presence of serum or in KOmedium. None of
these transcripts was significantly induced by EWS-FLI-1
in adult MSCs, irrespective of culture conditions (Fig. 4A;
data not shown). In contrast, a fourfold and fivefold
induction of OCT4 and NANOG, respectively, was ob-
served in all three pediatric populations tested in the
presence of serum (Fig. 4A). Induction of these two genes
was increased to 20-fold when the same cell populations
were cultured in KO medium (Fig. 4B), confirming that
the complete set of transcription factors required to
orchestrate genetic reprogramming of primary human
cells was induced in hpMSCEWS-FLI-1s, but not in their
adult counterparts. Unlike its effect on OCT4, NANOG,
MYC, and SOX2, EWS-FLI-1 did not induce KLF4 and
LIN28 in hpMSCs (data not shown). No induction of any
of these transcription factors was observed in cells
expressing the DBDM form of EWS-FLI-1, irrespective
of culture conditions.
Based on our recent demonstration that ESFTs contain
CSCs that express the stem cell marker CD133 (Suva
et al. 2009), and the notion that EWS-FLI-1 initiates ESFT
development, we addressed the possibility that EWS-FLI-1
expression may generate a hpMSC subpopulation with
ESFT CSC features. We first performed real-time PCR
analysis of CD133 expression levels in adult and
hpMSCEWS-FLI-1s cultured in the presence of serum or in
KOmedium. Slight induction of CD133 in adult cells and
a 15-fold induction in pediatric populations were ob-
served in the presence of serum (Fig. 4A). Strikingly, the
same pediatric populations grown in KO medium dis-
played a 250-fold increase of the CD133 transcript,
whereas no induction of CD133 was observed in cells
expressing the DBDM form of the fusion protein. Based
on these observations, hpMSCEWS-FLI-1s were tested for
cell surface expression of CD133, and, more specifically,
for its glycosylated epitope, AC133, which has been used
for CSC identification (Suva et al. 2009). hpMSCEWS-FLI-1s
grown in the presence of serum did not express the
AC133 epitope, as assessed by flow cytometry, despite
induction of the neural stem cell marker NGFR/p75 on
their surface (Fig. 4B). In contrast, FACS analysis of the
same cells cultured in KO medium revealed a stronger
cell surface induction of NGFR/p75, and, more remark-
ably, the generation of a subpopulation of hpMSCEWS-FLI-1s
expressing the glycosylated AC133 epitope of CD133
(Fig. 4D). The same result was obtained using three
additional hpMSCEWS-FLI-1 populations, and the percent-
age of MSCEWS-FLI-1s observed to be positive for CD133
(6%–10%) was comparable with that of CD133+ CSCs
found in primary ESFTs (Suva et al. 2009).
To verify that the appearance of CD133-positive cells
was not a reflection of the expansion of a rare subpopu-
lation of pre-existing CD133-positive cells that selec-
tively respond to EWS-FLI-1, we performed CD133 ex-
pression analysis by flow cytometry in three different
hpMSC populations cultured in KO medium before and
after CD133 magnetic microbead separation. This tech-
nique is reported to allow identification of even very rare
CD133-positive cells. Despite this approach, we could
not identify a CD133-positive cell fraction (Supplemental
Data 1D, left). In parallel, one of the hpMSC populations
was used to perform a flow cytometric time-course anal-
ysis of CD133 protein detectability upon EWS-FLI-1
miRNA145 and SOX2 in Ewing sarcoma
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expression. Consistent with the reprogramming hypoth-
esis, the CD133-positive subpopulation, comprising 6%
of the bulk culture, was observed to appear abruptly at
days 12–14 after EWS-FLI-1 expression, reaching a steady
state rapidly thereafter. Thus, we did not observe a grad-
ual emergence of CD133-positive cells that one might ex-
pect in the case of the expansion of a pre-existing CD133-
positive population. In contrast, no CD133-positive cells
were detectable in wild-type hpMSCs before or after
CD133 magnetic microbead separation within this time
frame (Supplemental Data 1D, right).
Identification of mechanisms that underlie the ob-
served difference in susceptibility to reprogramming
between adult and pediatric hMSCs would clearly be of
interest, as our current understanding of the regulation of
genetic reprogramming toward induced pluripotency is
only partial. Among the reported pathways involved, the
most relevant include those implicated in cell cycle and
proliferation control. Several recent reports have sug-
gested the cell cycle regulators Rb, p53, INK4a(p16), and
ARF(p14) to provide major biological roadblocks for
genetic reprogramming. We therefore compared the gene
expression profile of three different batches of wild-type
adult and pediatric MSCs (Supplemental Data 2), but
recorded no difference in the expression level of Rb, p53,
p16, or p14, as assessed by Affymetrix microarrays.
However, to exclude possible subtle differences in their
expression levels that may not have been detected by
Figure 4. EWS-FLI-1 expression in
hpMSCs grown in KO culture medium
generates a cell subpopulation displaying
the major in vitro features of ESFT CSCs.
(A) Adult and pediatric hMSCDBDMs and
hMSCEWS-FLI-1s were compared, by real-
time PCR analysis, for expression of
OCT4, NANOG, and CD133 that charac-
terize the ESFT CSC molecular pheno-
type. No induction was observed in
hMSCDBDMs. (B) FACS analysis of cell sur-
face CD133 expression in hpMSCEWS-FLI-1s,
showing that the 15-fold induction of
the CD133 transcript was not accompa-
nied by a concomitant appearance of its
glycosylated, stem cell-related epitope, de-
spite marked induction of the NGFR/p75
NCSC marker. (C,D) Experiments de-
scribed in A and B were repeated using
the same hpMSCEWS-FLI-1 population cul-
tured in KO medium. In cells cultured in
KO medium, EWS-FLI-1 strongly enhanced
OCT4, NANOG, and CD133 transcrip-
tion (C), and generated a hpMSCEWS-FLI-1
subpopulation expressing the glycosylated
cell surface CD133 epitope (D). (E) Real-
time PCR analysis of OCT4, NANOG,
and EWS-FLI-1 gene expression levels, in
CD133-positive and CD133-negative
hpMSCEWS-FLI-1-derived RNA, showing that
the CD133-positive fraction expresses a
higher level of OCT4 and NANOG, but
a nearly identical EWS-FLI-1 level. A sin-
gle representative experiment is shown.
All real-time PCR experiments were nor-
malized to cyclophyllin A and done in
triplicate. Error bars represent the SD
of three independent determinations. (F)
hpMSCEWS-FLI-1 CD133-positive fraction ex-
presses a higher level of the ESFT marker
LIPI, and of a panel of genes involved in
stemness. (G) FACS analysis of cell sur-
face CD133 expression of CD133-positive
or CD133-negative hpMSCEWS-FLI-1-derived
progeny, cultured in KO medium for 14 d
following the initial sorting. (H) Clonogenic assays were performed in triplicate as described in the Materials and Methods. Error bars
indicate the difference in the number of spheres formed in the three determinations. (Bottom right) Photomicrograph of a hpMSCEWS-FLI-1-
derived sphere. Magnification, 4003.
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microarrays, we performed real-time PCR analysis of the
same transcripts in adult and pediatric hMSCs. We
observed a modest but significant reduction of p14/p16
(but not p53 or Rb) transcript levels when hpMSCs were
cultured in KO compared with serum-containing me-
dium, whereas the same transcripts displayed no differ-
ence in expression level among adult MSCs grown in the
two culture conditions (Supplemental Data 3A).
In addition to displaying CD133 on their cell surface,
primary ESFT CSCs were observed to express high levels
of OCT4 and NANOG, generate both CD133-positive
and CD133-negative progeny, retain MSC differentiation
plasticity, and display sphere-forming ability in clono-
genic assays (Suva et al. 2009). To determine whether
CD133-positive hpMSCEWS-FLI-1s generated in KOmedium
display a CSC phenotype, we separated hpMSCEWS-FLI-1
CD133+ and CD133 fractions using magnetic beads, and
compared OCT4 and NANOG expression in the two
subpopulations. Consistent with the situation in primary
ESFT CSCs, both genes were more highly expressed in
CD133+ cells (Fig. 4E), despite an equal EWS-FLI-1 fusion
gene expression level in the two cell populations (Suva
et al. 2009). Microrarray gene expression comparison
further revealed higher expression of numerous genes
implicated in stem cell function and neuronal differenti-
ation in the CD133+ population (Supplemental Data 2).
Expression of several of these genes—including EOMES,
DCX, CTCFL, LEF1, and LIPI—was validated by quanti-
tative real-time PCR (Fig. 4F). To further assess the
similarity between hpMSCEWS-FLI-1s and ESFT CSCs,
hpMSCEWS-FLI-1 CD133+ and CD133 cells were sepa-
rated, and both populations were plated in KO medium.
After 2 wk of culture, cells derived from the two fractions
were analyzed by flow cytometry for expression of CD133.
Only the progeny of the CD133+ population contained
CD133+ cells whose percentage was comparable with that
in the initial unsorted population (Fig. 4G). These obser-
vations confirm that only the hpMSCEWS-FLI-1 CD133+
fraction possesses the ability, ascribed to CSCs, to generate
both CD133-positive and CD133-negative progeny.
Although no currently available in vitro test is specific
for CSCs, some growth properties, including spheroid
formation in culture, constitute candidate CSC features
(Singh et al. 2003; Todaro et al. 2007). We therefore tested
the ability of empty vector-infected or EWS-FLI-1-express-
ing hpMSCs to form spheres in KO medium. hpMSCs
were subjected to standard retroviral infection in the
KO reprogramming protocol (Maherali and Hochedlinger
2008), then detached and seeded as single-cell suspensions
in triplicate onto ultralow attachment 96-well plates. Be-
cause sphere formation is typically scored after a pro-
longed culture time (30 d in our experiments) following
seeding, the KO culture medium was supplemented with
three chemicals (PD0325901, CHIR99021, and A8301)
that were reported recently to allow stable culture of
reprogrammed hiPSs, precluding their senescence in vitro
(Feng et al. 2009). Addition of the three chemicals to the
culture medium did not modify the percentage of CD133+
cells generated by EWS-FLI-1 expression (data not shown).
hpMSCs infected with empty vector could not form
spheres, irrespective of the presence or absence of the
chemicals. In contrast, hpMSCEWS-FLI-1s cultured in KO
medium revealed spherogenic capacity similar to that
displayed by ESFT CSCs, which was further enhanced by
addition of the chemicals (Fig. 4H). Despite their sphero-
genicity, hpMSCs expressing EWS-FLI-1 failed to form
tumors in vivo, suggesting either the requirement for a
cooperating oncogenic event, or the possibility that the in
vitro KO microenvironment, while allowing the emer-
gence of a cellular subpopulation displaying CSC features,
still lacks the capacity to fully reproduce the original
cellular niche required for definitive transformation to-
ward ESFTs.
It is noteworthy that the efficiency of EWS-FLI-1-
mediated hpMSC reprogramming toward an ESFT CSC
phenotype decreased with the successive hpMSC pas-
sages. The capacity of the hpMSCs to form CD133-
positive cells upon EWS-FLI-1 expression was maximal
between passages 1 and 5 in vitro. Thereafter, this ability
progressively decreased between passages 5 and 10 and
was definitively lost after passage 15. The reprogramming
capacity was rapidly lost in cells submitted to freezing–
thawing cycles, and was also dependent on the age of the
pediatric donor, with younger patient-derived cells show-
ing higher proclivity to form CD133-positive cells. Thus,
compared with adult cells, the higher proliferation rate
of hpMSCs associated with reduction in their p14/p16
transcript levels upon culture in KO conditions may at
least partially explain their increased susceptibility to
reprogramming toward ESFT CSC imposed by EWS-FLI-1
expression. These observations are consistent with the
notion that cellular senescence impairs reprogramming,
and that a high replicative potential is crucial to induce
pluripotency in primary somatic cells (Banito et al. 2009).
EWS-FLI-1 induces higher SOX2, OCT-4, and NANOG
transcript levels in KO conditions through
repression of miRNA145
Enhanced induction of OCT4, NANOG, and SOX2 in
hpMSCEWS-FLI-1s cultured in KO medium could not be
explained by a mere difference in EWS-FLI-1 protein
expression levels, since they were found to be equal in
both culture conditions (Fig. 1D). We therefore addressed
the possible existence of a regulatory mechanism that
coordinately modulates expression of these genes in
hpMSCEWS-FLI-1s grown in the absence of serum. A re-
cently reported regulator of OCT4 and SOX2 expression
in human ESCs is miRNA145 (Chivukula and Mendell
2009; Xu et al. 2009). miRNA145 expression is low to
absent in undifferentiated human ESCs and progressively
increases during their differentiation (Chivukula and
Mendell 2009; Xu et al. 2009). miRNA145 itself is
reported to act directly on the 39 untranslated regions
(UTRs) of OCT4 and SOX2, resulting in repression of
both genes, thereby favoring the transition from ESCs to
embryonic bodies (Xu et al. 2009). To assess the putative
involvement of miRNA145 in the strongerOCT4, SOX2,
and NANOG induction observed in hpMSCEWS-FLI-1s
grown in the absence of serum, we compared miRNA145
miRNA145 and SOX2 in Ewing sarcoma
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expression in wild-type hpMSCs, cultured in the presence
or absence of serum, ESFT A673 and TC252 cell lines,
and primary ESFT CSC sphere cultures. Expression of
miRNA145 was found to be 95%–99% lower in the ESFT
cell lines A673 and TC252, respectively, than in hpMSCs,
whereas virtually no expression was detected in primary
ESFT CSC sphere cultures (Fig. 5A). Given that hMSCs
are candidate ESFT cells of origin (Riggi et al. 2008), we
addressed the possibility that the marked difference
in miRNA145 expression observed between wild-type
Figure 5. miRNA145 and EWS-FLI-1 ex-
ert a reciprocal control mechanism on
their mutual expression, as well as on
their common target genes, SOX2 and
OCT-4, which regulate ESFT cell differen-
tiation and tumorigenicity. (A) Real-time
PCR comparison of miRNA145 expression
in hpMSC, A673, and TC252 ESFT cell
lines and primary ESFT spheres. (B) EWS-
FLI-1 expression in hpMSCs cultured in
KO but not serum-containing conditions
causes a significant decrease in miRNA145
expression, as assessed by real-time PCR
analysis. (C, top panel) miRNA145 pro-
moter luciferase assay reveals that wild-
type EWS-FLI-1 but not its DBDM represses
miRNA145 promoter activity. Oct-4 ex-
pression was used as a positive control.
(Bottom panel) Western blot analysis in
the corresponding cellular lysates of EWS-
FLI-1, DBDM, and Oct-4 protein expres-
sion. (D,E) Retroviral-mediated overexpres-
sion of miRNA145 in A673 cells resulted in
a significant decrease in SOX2, NANOG,
and OCT4 expression levels, compared
with their empty vector-infected counter-
parts (D), and a concomitant increase in the
mesenchymal markers CD44 and CD73 on
the surface of these cells (E), as assessed by
real-time PCR and FACS analysis, respec-
tively. (F, left panels) miRNA145 specifi-
cally represses its target gene, FLI-1, in
a luciferase assay performed in HEK-293
cells engineered to express a luciferase re-
porter vector containing the human wild-
type FLI-1 39UTR. No repression in lucifer-
ase expression was observed when amutant
form (Mut) of the FLI-1 39UTR harboring
a deletion of miRNA145-binding sites was
used. Error bars represent the SD from three
independent experiments. (Right panel)
miRNA145 expression in A673 cells results
in a significant reduction of EWS-FLI-1
protein levels at 72 h post-infection. (G)
Endogenous Ago2 protein (top panel)
and EWS-FLI-1 mRNA (bottom panel) show
significant enrichment in Ago2 immuno-
precipitated material derived from cellu-
lar extracts of miRNA145-expressing but
not empty vector-infected A673 cells, as
assessed by Western blot and real-time PCR
analysis, respectively. (H) miRNA145 over-
expression in A673 cells causes a striking
reduction in tumor growth, compared with
cells infected with the corresponding empty
vector. (I) Schematic representation of the reciprocal negative regulatory loop between EWS-FLI-1 and miRNA145. Real-time PCR
experiments were normalized to either cyclophyllin A or Rnu6b, and done in triplicate. Error bars represent the SD of three independent
determinations.
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hpMSCs and ESFT cells could be due to the presence of
the EWS-FLI-1 fusion protein in the latter. hpMSCs were
grown in the presence or absence of serum, and the ex-
pression level of miRNA145 was compared between EWS-
FLI-1-expressing and empty vector-infected cells. Remark-
ably, introduction of EWS-FLI-1 resulted in significant
repression of miRNA145 transcript levels in hpMSC cul-
tured in KO but not serum-supplemented medium
(Fig. 5B), suggesting that the stronger induction of OCT4,
SOX2, and NANOG observed in hpMSCEWS-FLI-1s grown
in the absence of serum may result from repressive ac-
tivity of EWS-FLI-1 on the miRNA145 promoter.
miRNA145 expression in human ESCs is tightly regu-
lated in vivo through direct binding and repression of its
promoter by OCT-4 (Xu et al. 2009). This negative feed-
back loop allows maintenance of the high OCT4 and,
probably, SOX2 expression levels required to maintain
ESC in an undifferentiated state, a mechanism designated
recently as ‘‘repression of the repressor’’ (Xu et al. 2009). To
determine whether a similar mechanism might allow
EWS-FLI-1 to directly repress miRNA145 expression in
hpMSCs, we subjected the putative miRNA145 promoter
sequence to bioinformatics analysis using the TFSEARCH
tool (http://www.cbrc.jp/research/db/TFSEARCH.html).
Four putative ETS-binding motifs in the selected genomic
region were found. A luciferase reporter assay was then
performed using 293T cells engineered to express lucifer-
ase driven by the miRNA145 promoter as described pre-
viously (Xu et al. 2009). Introduction of EWS-FLI-1 into
these cells resulted in 60% reduction of luciferase expres-
sion, consistent with the ability of EWS-FLI-1 to repress
miRNA145 promoter activity, whereas introduction of
Oct-4 reduced expression by <40%.No effectwas observed
when the EWS-FLI-1 DBDMwas introduced into the same
cells (Fig. 5C).
To determine its role in ESFTs, miRNA145 was over-
expressed in A673 and TC252 cells using a retroviral
system (Supplemental Data 3B), and the effect on their
gene expression profile, differentiation status, and tumor-
igenic potential was assessed. In A673 cells, miRNA145
overexpression resulted in significant reduction of SOX2,
OCT4, and NANOG transcript levels, with concomitant
induction of the mesenchymal markers CD44 and CD73,
as assessed by real-time PCR and flow cytometry (Fig.
5D,E). In contrast, down-regulation of these stem cell
genes was less significant in TC252 cells and was not
associated with any changes in their mesenchymalmarker
profile (Supplemental Data 3C; data not shown), conceiv-
ably due to their lower baseline miRNA145 expression.
Several recent studies have reported the ability of
miRNAs to act through a negative regulatory feedback
loop by binding to the 39UTR of the genes that modulate
their own expression (Ordonez et al. 2009). We therefore
assessed the presence of putative miRNA145-binding
sites within the wild-type FLI-1 39UTR sequence, using
the TargetScan miRNA target prediction software. Three
highly and one poorly conserved putative miRNA145-
binding sites were identified (UTR nucleotide positions
88–94, 473–479, 513–519, and 265–271, respectively). (For
further details, see the Materials and Methods section and
TargetScan analysis at http://www.targetscan.org/cgi-bin/
targetscan/vert_50/view_gene.cgi?taxid=9606&gs=FLI1.)
To determine whether FLI-1 could be directly targeted
by miRNA145, we engineered the PGL3 luciferase re-
porter vector to contain either the human wild-type full-
length human FLI-1 39UTR or its mutant form harboring
a 6-base deletion in the four putative miRNA145 target
sites (Fig. 5F, top panel). In HEK293 cells, cotransfection
of the luciferase reporters with a retroviral vector express-
ing the miRNA145 resulted in a 60% reduction in lucif-
erase expression from the wild-type FLI-1 39UTR reporter.
In contrast, no significant reduction in luciferase activity
was observed from the mutated reporter compared with
control cells transfected with an empty vector (Fig. 5F,
bottom panel). No difference in EWS-FLI-1 transcript
levels was detected by real-time PCR in A673 cells after
miRNA145 overexpression (Fig. 5D), suggesting that the
effect of miRNA145 on EWS-FLI-1 expression may occur
at the translational level. EWS-FLI-1 protein levels were
therefore assessed by Western blot analysis in A673 cells
72 h post-infection with an empty vector or a miRNA145-
expressing retroviral vector. Significant reduction of the
EWS-FLI-1 protein level was observed upon expression of
miRNA145 (Fig. 5F), consistentwith the ability ofmiRNAs
to repress their target gene expression through either
mRNA degradation or translation inhibition mechanisms.
To rigorously probe for miRNA145 pairing to EWS-FLI-1
mRNA, Argonaute2 (Ago2), a component of the RISC
complex, was immunoprecipitated, along with isotype-
matched control antibody, from extracts of A673 cells
infected with either empty vector or miRNA145-express-
ing retroviral vector. The immunoprecipitated material
was analyzed byWestern blot and real-time PCR to detect
enrichment in Ago2 protein and FLI-1 mRNA, respec-
tively, as described previously (Ordonez et al. 2009).
Endogenous FLI-1 mRNA was significantly enriched in
the Ago2 immunoprecipitated fraction derived from the
A673 cells expressing miRNA145, compared with the
control empty vector-infected cells (Fig. 5G), confirming
direct interaction between miRNA145 and the EWS-FLI-1
39UTR in vivo.
Finally, we assessed the tumorigenicity of A673 cells
overexpressing miRNA145 and found a striking reduc-
tion in their tumor-forming capacity following subcuta-
neous injection into NOD-SCID mice (Fig. 5H), a result
that could be explained, at least in part, by miRNA145
repression of EWS-FLI-1 protein expression.
Taken together, these results demonstrate the existence
of a direct regulatory loop between miRNA145 and EWS-
FLI-1 that may allow the two partners to exert a reciprocal
control mechanism on their mutual expression, as well as
on the fusion protein target gene repertoire during the
initial steps of ESFT development (Fig. 5I).
SOX2 plays a critical role in ESFT differentiation
and pathogenesis
Although induction of a mesenchymal gene expression
profile in A673 cells expressing miRNA145, along with
reduction of their tumorigenic potential, could be explained
miRNA145 and SOX2 in Ewing sarcoma
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by the decrease in EWS-FLI-1 protein levels, it is conceiv-
able that one or several miRNA145 target genes may also
contribute to the observed phenotypic changes. Among
genes found to be modulated by miRNA145 in ESFT cells,
SOX2, a core reprogramming factor and EWS-FLI-1 target
gene, was induced more than a thousand-fold during the
emergence of a NCSC phenotype in hpMSCEWS-FLI-1s.
SOX2 plays a key role in CNS development, neuronal
differentiation, and neural stem cell maintenance (Graham
et al. 2003; Ellis et al. 2004; Fong et al. 2008), in addition to
genetic reprogramming of terminally differentiated cells
into hiPSs. Immunohistochemical analysis revealed ele-
vated Sox2 expression in a subpopulation of primary ESFT
cells, and a similar Sox2 expression pattern was observed in
tumors derived from subcutaneous injection into immu-
nocompromisedmice of theA673 andTC252 cell lines (Fig.
6A). Therefore, based on the notions that Sox2 fulfils a role
in bothneural stem cellmaintenance and genetic induction
of pluripotency, that ESFTs display features of NCSCs and
MSCs, and that primary hNCSCs have the ability to give
rise to MSCs, we addressed the possibility that Sox2 might
be functionally implicated in the reduced tumorigenic
potential as well as the differentiation changes along the
neuroectodermal–mesenchymal axis observed in A673
cells upon miRNA145 expression. To this end, we selected
two ESFT cell lines that are representative of the two
extremities of the ESFT differentiation spectrum: A673,
which displays a partial mesenchymal phenotype with
5%–30% CD44+, 4%–20% CD73+, and 0%–4% CD133+
cells; and TC252, which displays a more pronounced
neural phenotype with 0% CD44+ or CD73+ cells and
almost 100% CD133+ cells (data not shown). Consistent
with their tendency toward neuroectodermal differentia-
tion, TC252 cells were found to express a fivefold higher
level of SOX2 than A673 cells (Supplemental Data 1C).
To address the potential involvement of Sox2 in ESFT cell
fate determination, SOX2 expression was decreased in
both cell lines using two distinct SOX2-specific shRNAs,
and corresponding changes in NCSC and MSC differenti-
ation marker expression were assessed. In response to
the 50%–70% reduction of SOX2 transcript and protein
levels that was obtained (Fig. 6B,C), expression of all of
the NCSC markers tested—including NGFR/p75, AP2A,
AP2B, NESTIN, PAX3, NTRK1, and ALK—underwent a
significant decrease, as assessed by real-time PCR (Fig. 6D).
In contrast, expression of the MSC markers CD44 and
CD73 was strongly enhanced (Fig. 6D). Importantly, no
difference in EWS-FLI-1 mRNA and protein expression
Figure 6. SOX2 is directly involved in ESFT
differentiation and pathogenesis. (A) Immuno-
histochemical assessment of SOX2 expression
in primary ESFTs and cell line-derived tumors
grown in immunocompromised mice. Magni-
fication, 1003. (B,C) Real-time PCR (B) and
Western blot analysis (C) of SOX2 expression
following stable SOX2-specific shRNA expres-
sion in A673 and TC252 ESFT cell lines. The
experiments were performed using two differ-
ent SOX2-specific (SOX2 shRNA 1 and 2)
sequences and an unrelated shRNA control.
(D,E) Depletion of SOX2 in A673 and TC252
cells significantly decreased expression of nu-
merous NCSC markers, but not of EWS-FLI-1
protein levels, and was accompanied by an
increased expression of the hMSC markers
CD44 and CD73, as assessed by real-time
PCR (D, top panel), Western blot (D, bottom
panel), and FACS analysis (E). (F) A673 and
TC252 cell proliferation was significantly re-
duced after the stable knockdown of SOX2
shown in C. Means of triplicate values 6 SD
of three separate determinations are shown.
(G) Depletion of SOX2 in A673 cells causes
a striking reduction in tumor growth compared
with cells expressing unrelated RNAi se-
quences. Real-time PCR experiments were
normalized to cyclophyllin A and done in
triplicate. Error bars represent the SD of three
independent determinations.
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levels was noted between control and SOX2-depleted
cells, confirming that, in this context, the observed
induction of mesenchymal markers could not result from
a concomitant decrease in EWS-FLI-1 protein expression,
as observed upon miRNA145 expression or shRNA-
mediated EWS-FLI-1 depletion (Fig. 6D; Tirode et al.
2007). The increase in CD44 and CD73 and the decrease
in NGFR/p75 transcript levels in A673 cells were further
confirmed by flow cytometry (Fig. 6E), with CD44+ and
CD73+ cells rising from 4.1% to 8.2% and 7.7% to 14.1%,
respectively, andNGFR/p75+ cells decreasing from 95.1%
to 80.3%. The same trend was observed in TC252 cells,
where SOX2 depletion resulted in NGFR/p75 expression
decrease and the concomitant appearance of a CD73+ cell
subpopulation (Fig. 6E). The absence of CD44 expression
in TC252 may be linked to the significantly higher
baseline SOX2 expression level than in A673 cells, and
is consistent with the possibility that the partial SOX2
depletion by shRNA may have been insufficient for its
induction. Induction of SOX2 by EWS-FLI-1 expression in
hpMSCs may therefore play a critical role in the gener-
ation of the observed NCSC profile. Finally, the relation-
ship between the observed differentiation changes and the
proliferative and tumorigenic properties of the two cell
lines was assessed. Depletion of SOX2 resulted in a com-
parable decrease in proliferation of both cell lines (Fig. 6F).
More importantly, tumorigenicity of both cell lines was
reduced (Fig. 6G; Supplemental Data 3A), although not as
strongly as by miRNA145 overexpression. Taken together,
these data suggest that SOX2 may be a EWS-FLI-1 target
gene acting downstream from the fusion protein to regu-
late ESFT cell differentiation and tumorigenicity.
Discussion
Consistent with the notion that ESFTs are primarily
a pediatric and adolescent malignancy, pediatric hMSCs
infected with EWS-FLI-1-containing retroviral vectors
displayed a quantitatively and qualitatively different re-
sponse than adult MSCs to comparable expression levels
of EWS-FLI-1. In both pediatric and adultMSCs, EWS-FLI-1
induced a gene expression repertoire highly reminiscent
of that of primary Ewing sarcoma. However, many of the
genes induced in adult MSCs and believed to be impli-
cated in ESFT pathogenesis were more strongly induced
in hpMSCs. More importantly, numerous genes that are
among the most prominent ESFT markers were induced
in hpMSCEWS-FLI-1s but not in their adult counterparts.
Identification of novel candidate EWS-FLI-1 target
genes in pediatric MSCs
EWS-FLI1-induced transcriptome changes were far more
pronounced when the cells were cultured in KO medium
according to the protocol used to reprogram human
primary cells into iPSs. Not onlywas the level of induction
of ESFT-relevant genes higher, but several genes that were
not significantly induced in cells cultured in standard
medium were strongly up-regulated in cells cultured in
KO medium. Several of these genes—including ALK,
NTRK1, PBX1, and MEIS1 (Argiropoulos et al. 2007;
Janoueix-Lerosey et al. 2008)—are implicated in trans-
formation and tumorigenesis, and may bear relevance to
ESFT pathogenesis.
The anaplastic lymphoma kinase (ALK) is reported to
be expressed in ESFTs (Dirks et al. 2002), and has been
shown recently to be implicated in genetic predisposition
to neuroblastoma development (Mosse et al. 2008). Sim-
ilar to ALK, the nerve growth factor receptors p75/NGFR
andNTRK1 are expressed in ESFTs in addition to a variety
of human cancers, including prostate, pancreas, and
breast carcinoma, as well as gliomas (Reichardt 2006).
In breast cancer, NTRK1 is reported to promote growth,
migration, invasion, and metastasis (Lagadec et al. 2009),
and its overexpression alone is observed to result in
constitutive induction of its tyrosine kinase activity and
engagement of the downstreamPI3K–Akt andMAPkinase
signaling pathways (Lagadec et al. 2009). It is noteworthy
that neither NTRK1 nor ALK expression was detectable in
wild-type hpMSCs. Their induction by EWS-FLI-1 and
expression in primary ESFT may, along with IGF1R
engagement by IGF-1, be responsible for the observed
activation of PI3K–Akt andMAPkinase pathways in ESFT.
Therapeutic targeting of IGF-1R with monoclonal anti-
bodies has shown promise for the control of ESFT growth
in some patients, but resistance to IGF-1R blockade is
observed, possibly because of maintenance of PI3K–Akt
and MAP kinase pathway activity by other receptor
tyrosine kinases (RTKs). ALK, NGFR/p75, and NTRK1
provide plausible candidate RTKs whose signaling could
help bypass the requirement for IGF1 by ESFT cells. Their
inhibition may therefore have potential therapeutic rele-
vance as well as feasibility, in view of the recent emer-
gence of selective kinase inhibitors as an important class
of anti-cancer drugs (for review, see Janne et al. 2009;
Montagut and Settleman 2009).
Genetic reprogramming of hpMSCs by EWS-FLI-1
toward ESFT CSCs and miRNA145 modulation
Culture of hpMSCs expressing EWS-FLI-1 in the appro-
priate KO medium allowed not only identification of
hitherto unrecognized candidate EWS-FLI-1 target genes,
but resulted in the generation of a cellular subpopulation
recapitulating all of the major in vitro features of ESFT
CSCs. These include cell surface CD133 expression,
acquisition of asymmetric division capacity, and expres-
sion of a panel of genes involved in stem cell mainte-
nance, cellular reprogramming, and transformation. In-
terestingly, the emergence of this subpopulation was
preceded by the robust induction of the core reprogram-
ming genes OCT-4, NANOG, and SOX2, driven, in part,
by the EWS-FLI-1-mediated miRNA145 repression ob-
served when hpMSCEWS-FLI-1s are grown in the appropri-
ate microenvironment.
miRNAs represent a class of small (20- to 25-nucleotide
[nt]) noncoding RNAs that are key regulators of numer-
ous cellular events, including the balance between pro-
liferation and differentiation during tumorigenesis and
development. They generally inhibit target mRNAs by
miRNA145 and SOX2 in Ewing sarcoma
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repressing translation or reducing mRNA stability.
Among miRNAs that play a major role in supporting
stem cell properties, miRNA145 is of particular interest
because its expression has been shown recently to inhibit
human ESC pluripotency and self-renewal and to favor
lineage-restricted differentiation through repression of
SOX2 andOCT4. In hpMSCs, SOX2may constitute both
a direct and an indirect EWS-FLI-1 target gene whose
induction, along with that of the other core reprogram-
ming factors OCT4 and NANOG in hpMSCEWS-FLI-1s
grown in KO medium, appears to be fine-tuned by the
suppressive activity of EWS-FLI-1 on the miRNA145
promoter. Thus, modulation of miRNA expression pro-
vides an attractive link between stem cell maintenance,
induced pluripotency, and CSC biology. It is tempting to
speculate that the appearance of a subpopulation of
hpMSCEWS-FLI-1s bearing an ESFT CSC phenotype ob-
served in the present study may be a consequence of the
synergy between the direct action of EWS-FLI-1 on stem
cell genes and on miRNA-145. Only within the ap-
propriate microenvironment, represented by KO culture
medium here, can the expression level of the target
reprogramming genes attain the putative threshold re-
quired to initiate genetic reprogramming of hpMSCs into
ESFT CSCs.
Identification of several miRNA145 target sites in the
39UTR of the human FLI-1 transcript suggests that
miRNA145, in addition to modulating OCT4, NANOG,
and SOX2 expression levels after their initial induction
by EWS-FLI-1, may be further involved in a feedback
regulatory loop controlling EWS-FLI-1 expression itself.
Our experiments confirmed the existence of such a re-
ciprocal control mechanism, which seems to provide
tight regulation of expression of both partners as well as
that of their common target genes. The observation that
EWS-FLI-1 constitutes both a miRNA145 transcriptional
regulator and one of its direct targets offers new insight
into ESFT initiationmechanisms. The requirement for an
appropriate culture microenvironment that allows EWS-
FLI-1 to exert its repressing activity on the miRNA145
promoter indicates a link between EWS-FLI-1,miRNA145,
and the permissiveness of cells from which ESFTs origi-
nate. Thus, it is conceivable that initial expression of the
fusion protein during the very early steps of ESFT develop-
ment requires an environment that allows miRNA145
repression, resulting in stabilization of the EWS-FLI-1
protein and in enhancement of OCT4, NANOG, and
SOX2 expression. These events could endow the ESFT
cell of origin with CSC properties and ultimately result in
the conversion of cellular permissiveness for oncogene
expression to tumor-initiating ability.
SOX2 involvement in ESFT differentiation
and tumorigenesis
The changes in tumorigenic potential and differentiation
observed upon miRNA145 expression in ESFT cells may
be partially explained by the concomitant reduction in
EWS-FLI-1 protein levels. However, changes in expres-
sion of one or several EWS-FLI-1/miRNA145 target genes
could also be involved in the appearance of the observed
phenotype.
Based on its physiological role in neural stem cell
maintenance and differentiation (Graham et al. 2003;
Ellis et al. 2004; Fong et al. 2008), its participation in
genetic reprogramming (Jaenisch and Young 2008), and its
induction by EWS-FLI-1, Sox-2 provides an attractive
candidate to explain how expression of EWS-FLI-1 might
induce a partial neuroectodermal phenotype in a tumor
arising from transformed hpMSCs. Consistent with this
notion, even suboptimal depletion of SOX2 in two
distinct ESFTcell lines that represent the two extremities
of the Ewing sarcoma differentiation spectrum attenu-
ated their neuroectodermal phenotype with a concomi-
tant enhancement of mesenchymal markers. Interest-
ingly, SOX2 was also observed to participate in ESFT
cell proliferation and tumorigenesis, suggesting that,
among candidate EWS-FLI-1 target genes, it may play
a central role in ESFT pathogenesis.
Sox-2 has been identified recently as a lineage preserva-
tion oncogene that is able to promote squamous identity in
lung and esophageal squamous cell carcinomas (Bass et al.
2009), but the mechanism whereby it may promote
tumorigenicity in ESFT cells is unclear. It should be noted
that Sox-2 depletion did not have as strong an effect on
abrogation of ESFT cell tumorigenicity as did overexpres-
sion of miRNA-145, consistent with the notion that other
genes subject to miRNA-145 control may be implicated as
well. However, the ability of Sox-2 to control differentia-
tion may help generate a window of opportunity for the
activity of some of the survival and growth-promoting
genes induced by EWS-FLI-1. Numerous candidate EWS-
FLI-1 target genes have been proposed to participate in
primary cell transformation andmaintenance of the result-
ing tumor cells, but which of these genes are essential for
ESFT pathogenesis remains unclear. A plausible scenario is
that EWS-FLI-1-mediated transformation requires cooper-
ation between several EWS-FLI-1 target genes that can
occur only in a permissive cellular context. hpMSCs
can provide the microenvironment required for EWS-FLI-
1-mediated repression of miRNA-145 and induction of
SOX2, OCT4, and other reprogramming genes whose
combined activity may ensure maintenance of stem cell
properties that facilitate subsequent generation of CSCs.
Concomitant induction of the polycomb group gene
product EZH2 may abolish the response to oncogenic
stress triggered by overexpression of c-Myc, Alk, or Ntrk1,
whereas IGF-1 and possibly other growth factors may
secure cell survival. The combined effect of these target
gene products may provide a reasonable basis for MSC
transformation toward ESFT CSCs.
Taken together, our observations indicate that, in the
appropriate MSC microenvironment, a single aberrant
transcription factor generated by a reciprocal chromosomal
translocation is able to induce genetic reprogramming
toward a CSC phenotype by combined action on its target
genes and by directly modulating miRNA-145 expression.
To the best of our knowledge, this is the first report of
a mechanism whereby expression of a single oncogene in
a primary cell population generates the features of a CSC.
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Materials and methods
Cell culture
hpMSCs were obtained from femoral head bone marrow of four
pediatric patients undergoing limb axis correction surgery as
described previously (Suva et al. 2004, 2008; Riggi et al. 2008).
MSCs were cultured at low confluence in IMDM, 10% FCS, and
10 ng/mL PDGF-BB (PeProtechEC), and were tested for multi-
lineage differentiation into adipocytes, chondrocytes, and oste-
oblasts (Riggi et al. 2008). TC252 (kindly provided by Dr.
T. Triche) and A673 cell lines (American Type Culture Collec-
tion) were cultured in RPMI 1640 containing 10% FBS.
Cloning and RT–PCR
Retroviral vectors containing the V5-tagged cDNA clone encod-
ing the human EWS-FLI1 type 2 fusion and the EWS-FLI-1 R340N
DBDMwere described previously (Riggi et al. 2008). Oct-4 cDNA
was amplified from hpMSCs using SuperScript one-step RT–PCR
with the platinum Taq kit (Invitrogen). The amplified fragment
was digested with BglII and XhoI and inserted into a pMSCV Puro
retroviral vector (BD Biosciences Clontech). Primer sequences for
Oct-4 were forward BglII, GAAGATCTGCCACCATGGCGGGA
CACCTGGCTT, and reverse XhoI, CCGCTCGAGCGGTCAGT
TTGAATGCATGGGAGAGCCCA.
Retroviral infection
Expression of EWS-FLI-1V5 and DBDM in hMSCs was achieved
using Retroviral Gene Transfer and Expression (BD Biosciences
Clontech), according to the manufacturer’s recommendations.
Expression of the fusion genes and corresponding proteins were
tested at each time point in all of the batches of cells by RT–PCR
and Western blot analysis, respectively, using the mouse anti-V5
antibody. Infected cells were selected with 0.75 mg/mL puromy-
cin for 5 d, and the bulk of the resistant cells was used in
subsequent experiments. miRNA overexpression was performed
using HEK-293T cells. Cells were cotransfected with p-hTR or
miR145 (kindly provided by Dr. R. Agami), along with VSV-G
and the packaging vector, using FuGene6 (Roche) according to
the manufacturer’s recommendations. Supernatants of trans-
fected HEK-293T cells were collected after 72 h, filtered, and
used to infect target cells in the presence of polybrene (10 mg/mL).
Infected cells were selected with 1 mg/mL blasticidin for 5 d and
used for further experiments.
Western blot
Cell lysis, SDS-PAGE, blotting, and immunostaining were per-
formed by standard procedures, and protein bands were detected
using a chemoluminescent substrate kit (Pierce) according to the
manufacturer’s recommendations. Primarymouse anti-V5 epitope
(Invitrogen), mouse anti-FLI-1 (Calbiochem; Merck), mouse anti-
bactin (Sigma), mouse anti-Oct-4 (Santa Cruz Biotechnologies),
and mouse anti-a-tubulin (Calbiochem) monoclonal antibodies
and rabbit anti-SOX2 polyclonal antibody (Millipore; Chemicon)
were used. Secondary antibodies were HRP-conjugated goat anti-
mouse (Bio-Rad) and goat anti-rabbit immunoglobulin (Dako).
Reprogramming protocol
hpMSCs were cultured in standard FCS-containing medium and
infected following the standard retroviral protocol. Forty-eight
hours after the retroviral infection, hpMSCs were washed and
incubated in KO medium with or without addition of the chem-
icals PD0325901, CHIR99021, andA8301 (Stemgent). KOmedium
was composed of IMDM, 20% KO Serum Replacement (Invitro-
gen, GIBCO), 10 ng/mL PDGF-BB, 1% penicillin–streptomycin,
and 10 ng/mL human recombinant leukemia inhibitory factor (LIF)
(Millipore; Chemicon). For clonogenic assays, PD0325901 (0.5
mM), CHIR99021 (3 mM), and A8301 (0.25 mM) were added to the
KO medium.
Magnetic cell sorting and FACS analysis
Single MSC suspensions were incubated with CD133 microbeads
(Miltenyi) and separated using an autoMACS device (Miltenyi)
according to the manufacturer’s instructions. Prior to and fol-
lowing separation, samples were analyzed by flow cytometry
using CD133/2-PE (293C3, 1/10) antibody (Miltenyi) and isotype
control mouse IgG2b-PE (1/10) (Miltenyi) in a FACScalibur appa-
ratus (Becton Dickinson). Further flow cytometry was performed
using rat anti-human CD44-PE (eBioscience), mouse anti-human
CD73-PE (BD Pharmingen), mouse anti-human NGFR/p75
(Miltenyi), and isotype control rat IgG2b-PE (BD Pharmingen)
and mouse IgG2b-PE antibodies (BD Pharmingen).
Affymetrix GeneChip arrays analysis and statistical analysis
of the expression data
Total RNAwas extracted 12 d after infection and selection, from
each of the EWS-FLI-1 and vector-containing hMSC batches,
using the RNeasy Mini Kit (Qiagen) according to the manufac-
turer’s recommendations. RNA quality was verified by an Agilent
RNA 600 nanoassay and by measuring the 260/280 absorbance
ratio. Quality-tested total RNA was used by the Lausanne DNA
Array Facility (DAFL) to perform gene expression profile analysis
on Affymetrix HG-U133 Plus 2.0 Arrays following the manufac-
turer’s recommendations (http://www.unil.ch/dafl). For each of
the four freshly isolated batches of hMSCs, Affymetrix analysis
was performed on EWS-FLI-1V5-expressing cells and on empty
vector control cells. Gene expression data were obtained with the
RMA method (Irizarry et al. 2003) using the Affymetrix Power
Tools suite. By comparing each EWS-FLI-1V5-expressing batch
with the same batch transfected with the empty vector, we
obtained, for each probe set in the chip, four measurements of
the expression ratio. Differentially expressed genes were then
identified with the rank product method (Breitling et al. 2004) as
implemented in the ‘‘RankProd’’ Bioconductor package (Hong
et al. 2006). Probe sets identified as differentially expressed with
a false discovery rate (FDR) of 1% were retained for further
analysis. For cells cultured in KO medium, probe sets with an
expression fold change >2 or <0.5 were considered as differentially
expressed. To compare our differentially expressed genes with the
ones identified in other studies, we first used the annotation files
provided by Affymetrix (version 29) to translate the lists of probe
sets into lists of Entrez gene IDs. Such lists were used to compare
our results with the ones in the published databases (Staege et al.
2004; Baird et al. 2005), translated when necessary into Entrez
gene IDs using the GenBank accession numbers reported by
Staege et al. (2004) and Baird et al. (2005). Statistical significance
of the overlap between lists of genes was evaluated with a two-
sided Fisher test and Bonferroni correction for multiple testing.
Real-time quantitative RT–PCR
cDNA was obtained using M-MLV reverse transcriptase and
RNase H minus (Promega). Typically, 500 ng of template total
RNA and 250 ng of random hexamers were used per reaction.
Real-time PCR amplification was performed using a TaqMan
Universal PCR mastermix and Assays-On-Demand gene expres-
sion products or Power SYBR mix and specific PCR primers in an
miRNA145 and SOX2 in Ewing sarcoma
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ABI Prism 7900 instrument (Applied Biosystems). Relative quan-
tification of each target, normalized to an endogenous control
(Cyclophyllin A), was performed using a comparative Ct method
(Applied Biosystems). Probes used included human IGF1, NKX2-2,
GRP, NPY1R, EZH2, SOX2, NTRK1, ALK, NGFR/p75, OCT-4,
NANOG, CD133, CCK, MEIS1, PBX1, CD73, and CD44 (Assays-
On-Demand gene expression). SYBR Green gene expression quan-
tification for EWS-FLI-1, AP2a, AP2b, NESTIN, PAX3, RET,
FOXD3, POUF4F1, TWIST, EOMES, DCX, CTCFL, LEF1, and
LIPI was achieved using published primer sequences (Peter et al.
2001; Thomas et al. 2008). SYBR Green primer sequences for the
quantification of human p53, Rb, p16, and p14 transcripts were as
follows: p53: fwd, 59-CCCAGCCAAAGAAGAAACCA-39, and
rev, 59-TTCCAAGGCCTCATTCAGCT-39; Rb: fwd, 59-GAGCTT
GGTTAACTTGGGAGAA-39, and rev, 59-CAGATTCCCCACAG
TTCCTTT-39; p14: fwd, 59-GGCCCTCGTGCTGATGCTAC-39,
and rev, 59-TGGAGCAGCAGCAGCTCCGC-39; p16: fwd,
59-CACCGAATAGTTACGGTCGG-39, and rev, 59-GCACGGGT
CGGGTGAGAGTG-39. For miRNA quantification, total RNA
containing miRNAs was extracted using a miRNAeasy kit (Qia-
gen) according to the manufacturer’s instructions. miRNA was
amplified using a miRNA reverse transcription kit (Applied Bio-
systems). RT–PCR amplification was performed as described and
was normalized using RNU6B as an endogenous control. Probes
included RNU6B and hsa-miR-145 (Applied Biosystems).
Clonogenic assay
Empty vector-infected or EWS-FLI-1-expressing hpMSCs were
plated as single cells in four 96-well plates and cultivated for
30 d in standard FCS-containing or stem cell KOmedium. Sphere
formation was scored 30 d later.
SOX2 knockdown and in vitro MTT assay
The sequence of the 19-nt shRNA 1 targeting the human SOX2
sequence was described previously as sequence A (Fong et al.
2008); the sequence of shRNA 2 was 59-AGACTAGGACTGA
GAGAAA-39. Sense and antisense oligonucleotideswere annealed
to form duplexes and were inserted into the pSIREN-Retro Q
retroviral vector (BD Biosciences Clontech) according to the
manufacturer’s recommendations. Briefly, plasmids containing
SOX2 or control shRNA were transfected into GP2 packaging
cells to produce the virus used to infect the TC252 and A673
target cell lines. Infected TC252 and A673 cells were selected for
5 d with 1 mg/mL and 2 mg/mL puromycin, respectively, and the
level of SOX2 knockdown was assessed by real-time quantitative
PCR and Western blot analysis. Densitometric analysis was
performed using the public domain image processing and analysis
program NIH Image J (http://rsb.info.nih.gov/ij). For the MTT
assay, TC252 and A673 cells infected with pSIREN containing
SOX2 or control shRNA were incubated in 24-well plates, and
their proliferation was tested with the CellTiter Non-Radioactive
Cell Proliferation Assay (Promega) according to the manufac-
turer’s recommendations.
Luciferase reporter assay
A luciferase reporter assay was performed as described pre-
viously with some modifications (Cironi et al. 2008). Briefly,
for the miRNA145 promoter assay, HEK-293Tcells were cotrans-
fected with empty pTransluc (kindly provided by Dr. K.S. Kosik)
or pTransluc miR-145 promoter (purchased from Addgene) along
with empty pMSCV puro, pMSCV EWS-FLI1, pMSCV EWS-FLI1
R340NDBDM, or pMSCVOCT-4 using FuGene 6 (Roche). For the
assessment ofmiRNA145 binding to the FLI-1 39UTR, a 600-base-
pair (bp) PCR fragment of the human FLI-1 39UTR was amplified
and cloned into theXbaI site of the pGL3 control vector (Promega).
Amutant form of this construct, harboring the deletion of the four
miRNA145-binding sites, was obtained by site-directed mutagen-
esis (QuickChange kit; Stratagene), and HEK-293Tcells were then
cotransfected with either control or miR145 expression vectors.
Forty-eight hours after transfection, luciferase activity was mea-
sured using the Luciferase Assay System (Promega) according to
the manufacturer’s recommendations. Normalization was per-
formed as described previously (Cironi et al. 2008). All experi-
ments were performed in triplicate.
Tumorigenicity assays
Six NOD/SCID IL2 receptor common g chain knockout mice
were anaesthetized and 2 3 106 empty vector-infected or EWS-
FLI-1-expressing hpMSCs were injected under the renal capsule.
All mice were sacrificed 3 mo later, and the kidneys were
removed at autopsy for histological analysis. For the assessment
of the tumorigenic potential of SOX2-depleted and miRNA145-
overexpressing ESFT cell lines, six NOD/SCID mice were
injected subcutaneously with 2 3 106 or 1 3 106 of control,
shRNA-infected, or miRNA145-overexpressing TC252 or A673
cells, respectively, and the animals were sacrificed 3–4 wk after
injection. All tumors were resected at autopsy and sectioned for
histological analysis. Experimental protocols involving mice
were approved by the Etat de Vaud, Service Ve´te´rinaire, autho-
rization number VD1477.2.
Immunohistochemistry
Paraffin-embedded sections of primary Ewing’s sarcoma, TC252-,
and A673-derived tumors were stained with rabbit anti-human
SOX2 polyclonal antibody (1:1000 dilution; Millipore, Chemi-
con). For the detection of LIPI expression in hpMSCs, empty
vector-infected or EWS-FLI-1-infected cells were selected with
puromycin, seeded onto histological slides, fixed with PFA, and
stained with mouse polyclonal anti-LIPI antibody (Abnova Cor-
poration). Horseradish peroxidase staining was performed using
biotin-conjugated goat anti-rabbit or rabbit anti-mouse Ig (Vector
Laboratories), and was revealed with a DAKO DAB Kit (Dako).
Ago2 immunoprecipitation
Ago2 immunoprecipitation was performed as described previ-
ously with some modifications (EZH2 mol cell). Briefly, A673
were infected with either empty control hTR- or miR145-express-
ing vectors. After 72 h, cells were harvested and lysed, and the cell
extracts were incubated with 2 mg of Ago2 (Wako Chemicals) or
mouse IgG (Sigma) antibodies for 2 h. The immunoprecipitated
complex was subsequently incubated with precleared protein-G
sepharose beads for 1 h, after which beads were washed and total
RNA was extracted using Trizol reagent. Real-time PCR was
performed using the following primers: hFLI-1 Fwd, 59-GGGCA
CAAACGATCAGTAAGA-39, and hFLI1 Rev, 59-GCTAGGCGA
CTGCTGGTC-39, and normalized to RNA 18S (Assays-On-
Demand gene expression; Applied Biosystems).
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